SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 10, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $989K total
Actionable Insight • Neutral

The CEO's sales are consistent with routine post-exercise liquidity and tax withholding, not a bearish signal. The EVP's sale is modest. Monitor next quarter's Tyvaso DPI growth trajectory and ralinepag NDA outcome for fundamental catalysts; insider activity alone does not warrant a trade.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$515.50
T+0 close · Aug 10, 2026 · via day close
Latest settled
+18.04%
T+60 · $608.49
Vs SPY
+18.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $515.50entry
  2. T+1 · 3mo ago −0.73%α −0.98% · $511.72
  3. T+5 · 3mo ago +0.54%α +0.94% · $518.27
  4. T+20 · 2mo ago −1.68%α −0.62% · $506.82
  5. T+60 · 13d ago +18.04%α +18.53% · $608.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Martine Rothblatt and EVP Paul Mahon sold a combined $989K in open-market shares within two days of United Therapeutics' Q2 2026 earnings, which showed a 2% revenue miss and 4% decline in total Tyvaso sales. While the dollar amount is trivial relative to the $22.7B market cap (0.004%), the timing, immediately after a mixed earnings report, and the CEO's exercise of 9,500 options for cashless net-share settlement suggest the sales are primarily liquidity-driven rather than a bearish signal. The cluster is neutral: the CEO's sales follow a typical post-exercise pattern, and the EVP's sale is modest. No material directional read-through for the stock.

Key Financial Metrics

Direction
selling
Total Value
$5.7M
Insiders
2

Key Facts

  • CEO Martine Rothblatt sold 632 shares at $539.14, 625 at $538.54, and 2,781 at $531.30 among 14 open-market sales on 2026-08-07, totaling ~$4.6M
  • CEO also exercised 9,500 options at $0 (non-cash) and 9,500 options at $135.42 (cash exercise of $1.29M) on the same day
  • EVP Paul Mahon sold 1,360 shares at $515.93 and 780 shares at $517.94 on 2026-08-06, totaling ~$1.1M
  • Total open-market sales by both insiders: ~$5.7M, or 0.025% of $22.7B market cap
  • Q2 2026 revenue of $783.3M missed consensus of $804.6M; diluted EPS of $7.27 beat $6.86 estimate

Financial Impact

Insider sales total ~$5.7M, immaterial relative to $22.7B market cap (0.025%)

insider_sales_volume

Risk Factors

  • Revenue miss in Q2 2026 driven by 4% Tyvaso decline may pressure near-term sentiment
  • CEO's large option exercise and concurrent sales could be misinterpreted as insider pessimism
  • No buys in the cluster, absence of insider buying post-earnings is a mild negative
  • Pipeline catalysts (ralinepag, Tyvaso IPF) are binary events with regulatory risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1786435291109

Track record

123 reports on UTHR

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens Wed (10h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026